European Medicines Agency accepts six new medicines in April meeting

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has accepted six new medicines at its April meeting. Zavicefta Ceftazidime/avibactam (Zavicefta), a new treatment option against multi-drug resistant bacteria. The medicine is to be used in adult patients with intra-abdominal infection, urinary tract infection, as well as pneumonia acquired in a hospital setting. It is also indicated for the treatment of adults with infections caused by certain Gram-negative bacteria, for which there are only limited treatment options Daclizumab (Zinbryta) for the treatment of relapsing forms of multiple sclerosis Opicapone (Ongentys) for the treatment of Parkinson’s disease and